[
    [
        {
            "time": "2018-03-15",
            "original_text": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "outpaces",
                    "stock market gains"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Peninsula Alzheimer's fighter hunts $150 million IPO",
            "features": {
                "keywords": [
                    "Peninsula",
                    "Alzheimer's",
                    "IPO"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Peninsula Alzheimer's fighter hunts $150 million IPO",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Neurocrine Gives Ingrezza Sales View, Updates on Pipeline",
            "features": {
                "keywords": [
                    "Neurocrine",
                    "Ingrezza",
                    "sales view",
                    "pipeline updates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Neurocrine Gives Ingrezza Sales View, Updates on Pipeline",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Neurocrine Biosciences Is a Pharma Stock to Watch",
            "features": {
                "keywords": [
                    "Neurocrine Biosciences",
                    "pharma stock"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Neurocrine Biosciences Is a Pharma Stock to Watch",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Notable ETF Inflow Detected - SDY, T, O, ABBV",
            "features": {
                "keywords": [
                    "ETF inflow",
                    "SDY",
                    "T",
                    "O",
                    "ABBV"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividend stocks"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Notable ETF Inflow Detected - SDY, T, O, ABBV",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-25",
            "original_text": "As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock",
            "features": {
                "keywords": [
                    "patent expirations",
                    "AbbVie"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "Gilead (GILD) Collaborates With Yuhan for NASH Candidates",
            "features": {
                "keywords": [
                    "Gilead",
                    "collaborates",
                    "Yuhan",
                    "NASH candidates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Gilead (GILD) Collaborates With Yuhan for NASH Candidates",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-03",
            "original_text": "Jim Cramer Gives His Opinion On Ciena, Momo, Qualcomm And More",
            "features": {
                "keywords": [
                    "Jim Cramer",
                    "opinion",
                    "Ciena",
                    "Momo",
                    "Qualcomm"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Jim Cramer Gives His Opinion On Ciena, Momo, Qualcomm And More",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-22",
            "original_text": "Today's Research Reports on Trending Tickers: AbbVie and Allergan",
            "features": {
                "keywords": [
                    "research reports",
                    "trending tickers",
                    "AbbVie",
                    "Allergan"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Today's Research Reports on Trending Tickers: AbbVie and Allergan",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-15",
            "original_text": "The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Bristol-Myers",
                    "Celgene",
                    "Merck",
                    "Pfizer",
                    "AbbVie"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-01-10",
            "original_text": "3 Bargain Stocks You Can Buy Right Now",
            "features": {
                "keywords": [
                    "bargain stocks",
                    "buy right now"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3 Bargain Stocks You Can Buy Right Now",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]